Follow Us

POTOMAC, Maryland – June 9, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that Ascendiant Capital Markets

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis

Continued Advancement of CALMA Phase 2 Trial

Research highlights advanced imaging analytics that may support Alzheimer’s disease monitoring, patient stratification, and future therapeutic development.

Understanding why some Alzheimer’s patients decline faster than others, even with similar levels of tau pathology remains one of the field’s most pressing questions.